spacer
home > ebr > spring 2003 > signal transduction in breast cancer: silencing the cross-talk
PUBLICATIONS
European Biopharmaceutical Review

Signal Transduction in Breast Cancer: Silencing the Cross-Talk

Signal transduction pathways mediate the ability of cells to respond to hormonal and environmental stimuli. Diverse and rapid cellular responses to external stimuli may involve proliferation, differentiation, migration or programmed cell death. In the normal cell a tightly regulated cross-talk network between multiple independent and convergent pathways maintains the cell in a specific developmental and functional pathway. Aberrations in these signal transduction pathways can result in cellular transformation. Furthermore, experimental evidence suggests that pathway cross-talk augments the tumorigenic and metastatic potential of transformed cells. Additionally, cross-talk between diverse signal transduction pathways appears to play a critical role in the progression and therapeutic resistance of breast cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Frank E Jones, Department of Structural and Cellular Biology, Dr Matthew E Burow, Department of Medicine (Hematology & Medical Oncology), Department of Surgery, and Dr Steven M Hill, Department of Structural and Cellular Biology, at Tulane Cancer Center

Dr Frank E Jones undertook his post-doctoral training at Yale University within the Department of Pathology. He accepted a position as Assistant Professor at Tulane University in the Department of Structural and Cellular Biology in June 2001.

Dr Jones' research interests focus on the development of mouse models to study the molecular mechanisms contributing to metastatic breast, ovarian and prostate cancers.

Dr Matthew E Burow carried out his post-doctoral studies at the Tulane/Xavier Center for Bioenvironmental Research and was subsequently appointed as a Research Assistant Professor in the Department of Pharmacology in 2000. In 2002 Dr Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine, with an appointment as an Adjunct Assistant Professor in the Department of Surgery. His primary research interests focus on understanding the molecular mechanisms that control oestrogen receptor mediated gene expression and anti-oestrogen resistance in breast carcinoma cells, as well as the way that cell survival and apoptotic signalling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.

Dr Steven M Hill undertook his post-doctoral training at the University of Texas Health Sciences Center, San Antonio, in the Medical Oncology section of the Department of Medicine under the tutelage of the late Dr William L McGuire. Dr Hill joined Tulane University in 1989 as an Assistant Professor and is currently Professor of Structural and Cellular Biology at Tulane University Health Sciences Center and holds the Edmond and Lily Safra Chair for breast cancer research. Dr Hill's general research interests focus on defining the mechanisms of cross-talk between G-protein coupled receptor signalling pathways and steroid hormone receptor signalling pathways in breast cancer.
spacer
Dr Frank E Jones
spacer
spacer
spacer
Dr Matthew E Burow
spacer
spacer
spacer
Dr Steven M Hill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement